Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
New strategies trying to achieve blood pressure control and consequently reduce
cardiovascular risk in resistant hypertensive subjects are promising. In this context, the
SGLT2 inhibitor dapagliflozin, not yet investigated in resistant hypertension, arises as a
potential drug in order to impact on blood pressure levels, as well as target organ damage
and adiposity in this high-risk population.
Phase:
Phase 4
Details
Lead Sponsor:
University of Campinas, Brazil
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo